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ABSTRACT
Background Following exposure to TB, contacts are
screened to target preventive treatment at those at high
risk of developing TB. The UK has recently revised its
recommendations for screening and now advises a 5 mm
tuberculin skin test (TST) cut-off irrespective of age or
BCG status. We sought to evaluate the impact of BCG
on TST responses in UK children exposed to TB and the
performance of different TST cut-offs to predict interferon
γ release assay (IGRA) positivity.
Methods Children <15 years old were recruited from
11 sites in the UK between January 2011 and December
2014 if exposed in their home to a source case with
sputum smear or culture positive TB. Demographic
details were collected and TST and IGRA undertaken.
The impact of BCG vaccination on TST positivity was
evaluated in IGRA-negative children, as was the
performance of different TST cut-offs to predict IGRA
positivity.
Results Of 422 children recruited (median age
69 months; IQR: 32–113 months), 300 (71%) had been
vaccinated with BCG. BCG vaccination affected the TST
response in IGRA-negative children less than 5 years old
but not in older children. A 5 mm TST cut-off
demonstrated good sensitivity and speciﬁcity in
BCG-unvaccinated children, and an excellent negative
predictive value but was associated with low speciﬁcity
(62.7%; 95% CI 56.1% to 69.0%) in BCG-vaccinated
children. For BCG-vaccinated children, a 10 mm cut-off
provided a high negative predictive value (97.7%; 95%
CI 94.2% to 99.4%) with the positive predictive value
increasing with increasing age of the child.
Discussion BCG vaccination had little impact on TST
size in children over 5 years of age. The revised TST
cut-off recommended in the recent revision to the UK
TB guidelines demonstrates good sensitivity but is
associated with impaired speciﬁcity in BCG-vaccinated
children.
BACKGROUND
Following household exposure to an infectious
adult with pulmonary TB, up to half of all children
living with this source case will themselves have
evidence of sensitisation to Mycobacterium
tuberculosis. This is usually manifest as a positive
immune test in either the skin or blood.1 TB infec-
tion implies that organisms are dormant within the
body and are not causing disease; the child is clinic-
ally well with a normal chest radiograph. In the
majority of children, disease never develops but
over time, in a proportion, the mycobacteria will
overcome the immune-mediated containment and
the child will become ill with TB disease.2 3
Certain risk factors increase the likelihood of pro-
gressing from asymptomatic TB infection to TB
disease. These include young age and suppression
of the immune system.4 5 Over 50 years ago it was
demonstrated that by providing drug therapy to
individuals with evidence of TB infection, the risk
of progression to TB disease could be signiﬁcantly
reduced.6 The use of daily isoniazid, given for at
least 6 months, has subsequently been demon-
strated in a large number of studies to be effective
in reducing the risk of disease progression in those
with TB infection for HIV-positive7 and
HIV-negative contacts.8
The organism M. tuberculosis is not detectable in
individuals with TB infection. Currently available
Key messages
What is the key question?
▸ The impact of BCG vaccination on tuberculin
skin test response is poorly understood in
children; we set out to determine the impact of
previous BCG vaccination on tuberculin skin
test response in UK children following
household exposure to an infectious case of TB.
What is the bottom line?
▸ The effect of infant BCG vaccination on the size
of the tuberculin skin test wanes as children
get older.
Why read on?
▸ The revised UK national guidance of using a
5 mm tuberculin skin test cut-off results in
impaired speciﬁcity in BCG-vaccinated children.
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diagnostic tests rely on demonstrating evidence of the presence
(or absence) of prior immunological sensitisation. Traditionally,
the tuberculin skin test (TST) has been used for this purpose. In
the TST, a crude mixture of mycobacterial antigens is injected
into the dermis of the skin in the forearm and the presence of a
skin reaction at the site of injection ‘read’ at 48 h for evidence
of a type IV delayed hypersensitivity reaction, signifying
immunological memory to antigens within the tuberculin. These
antigens, however, are not unique to M. tuberculosis; some are
also found in BCG and environmental, non-tuberculous myco-
bacteria.9 Newer tests, such as the interferon γ release assays
(IGRAs), measure either the quantity of interferon γ released by
T cells or the number of T cells which release interferon γ, after
stimulation by M. tuberculosis-speciﬁc antigens. Consequently,
they have been found to have superior speciﬁcity.10
Until 2005, it was advised that all children in the UK be given
BCG between the ages of 10 and 14 years. In addition, targeted
vaccination, to be given soon after birth, was advised for chil-
dren deemed at increased risk of TB exposure. This included
children living in areas of high TB prevalence and those born
within families from high incidence countries.11 From 2005,
universal BCG vaccination was no longer recommended; tar-
geted neonatal vaccination continued. In 2006 the National
Institute for Health and Care Excellence (NICE) published guid-
ance on the management of TB contacts.12 NICE suggested a
stepwise screening strategy for TB infection in childhood con-
tacts, using combinations of TST and IGRA with different algo-
rithms for children of different ages, resulting in signiﬁcant
complexities in management. The 2006 NICE guidance also
suggested using different TST cut-offs for children who had pre-
viously been vaccinated with BCG (15 mm induration) and
those who had not been (6 mm induration). The rationale for
this was that a prior BCG immunisation might lead to false-
positive results and impaired speciﬁcity of the TST. However, it
was felt that the size of the induration would differentiate
between BCG and TB infection—the larger the induration, the
greater the probability that the response was due to TB infec-
tion.13 It may be that part of this recommendation is a legacy
from a time when BCG was given to adolescents, where BCG
would have a signiﬁcant impact on TST response. Many clini-
cians were, however, concerned that a response of less than
15 mm in a BCG-vaccinated child might still indicate TB infec-
tion, and should not be ignored. International guidelines recom-
mend a cut-off of 10 mm induration for a positive TST result
regardless of BCG status.14 In early 2016, NICE updated its
guidance and suggested that a TST cut-off of 5 mm be used irre-
spective of BCG vaccination status in all ages of children.15
Prior to the advent of IGRA tests, it was not possible to evalu-
ate the impact of a previous BCG vaccination on the TST
response in TB contacts as it was not possible to determine
whether a TST response was due to the prior BCG vaccination
rather than TB infection. However, by evaluating TST responses
in child contacts of TB cases shown to be IGRA-negative, the
contribution of BCG can now be more precisely documented.
While fully acknowledging that no gold standard for TB infec-
tion exists, we felt that a negative IGRA test result would act as
a proxy measure for lack of sensitisation to M. tuberculosis. We
therefore set out to answer two questions. First, to determine
Table 1 Demographic and clinical characteristics of children in the study
IGRA status BCG status
Characteristic IGRA negative (%) IGRA positive (%) BCG unvaccinated (%) BCG vaccinated (%) Total (%)
Total 314 (100) 108 (100) 122 (100) 300 (100) 422 (100)
Gender
Male 164 (52.2) 52 (48.2) 64 (52.5) 152 (50.7) 216 (51.2)
Female 150 (47.8) 56 (51.9) 58 (47.5) 148 (49.3) 206 (48.8)
Median age in months (IQR) 60 (25–104) 94 (61–136) 71 (37–118) 68 (30–110) 69 (32–113)
Ethnicity
White 69 (22.0) 36 (33.3) 84 (68.9) 21 (7.0) 105 (24.9)
Indian 38 (12.1) 10 (9.3) 3 (2.5) 45 (15.0) 48 (11.4)
Pakistani 60 (19.1) 18 (16.7) 8 (6.6) 70 (23.3) 78 (18.5)
Bangladeshi 34 (10.8) 4 (3.7) 2 (1.6) 36 (12.0) 38 (9.0)
Black Caribbean 2 (0.6) 0 0 2 (0.7) 2 (0.5)
Black African 68 (21.7) 27 (25.0) 12 (9.8) 83 (27.7) 95 (22.5)
Black Other 8 (2.6) 6 (5.6) 5 (4.1) 9 (3.0) 14 (3.3)
Chinese 1 (0.3) 0 0 1 (0.3) 1 (0.2)
Mixed/other 34 (10.8) 7 (6.5) 8 (6.6) 33 (11.0) 41 (9.7)
HIV status*
Negative 280 (89.2) 90 (83.3) 100 (82.0) 270 (90) 370 (87.7)
Positive 0 0 0 0 0
Not tested 34 (10.8) 18 (16.7) 22 (18.0) 30 (10) 52 (12.3)
Born in the UK
No 36 (11.5) 25 (23.2) 12 (9.8) 49 (16.3) 61 (14.5)
Yes 278 (88.5) 83 (76.9) 110 (90.2) 251 (83.7) 361 (85.6)
Type of IGRA
QuantiFERON-TB Gold 190 (60.7) 71 (65.7) 84 (68.9) 177 (59.2) 261 (62.0)
T-SPOT.TB 124 (39.3) 37 (34.3) 38 (31.2) 122 (40.8) 161 (38.0)
*HIV status was known in 370 children. No children were known to be HIV positive.
IGRA, interferon γ release assay.
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the inﬂuence of prior BCG vaccination on TST responses in
IGRA-negative children living in the UK who were being
screened because of household exposure to an infectious TB
case. Second, to evaluate the sensitivity, speciﬁcity, positive pre-
dictive value (PPV) and negative predictive value (NPV) of dif-
ferent TST cut-offs to predict IGRA positivity in BCG
vaccinated and unvaccinated children of different ages.
METHODS
Study setting
This investigation was carried out within a larger study, the
NIHR-funded IGRA Kids Study (NIKS), which sought to evalu-
ate the NPV of IGRA to predict incident TB disease in children
exposed to TB in the UK. Sites included ﬁve paediatric TB
clinics in London, together with paediatric TB clinics in
Southampton, Bristol, Birmingham, Manchester, Glasgow and
Newcastle. All children (<15 years) presenting to one of the 11
participating centres between 1 January 2011 and 31 December
2014 were eligible for recruitment if they had a history of
household exposure to a source case with pulmonary sputum
smear or culture positive TB.
Study procedures and deﬁnitions
Following the diagnosis of a source case of infectious pulmonary
TB, household contacts were identiﬁed and screened. Screening
aimed to identify contacts already unwell with TB disease and
asymptomatic individuals eligible for treatment of TB infection.
Families were invited to participate in the study and written
informed consent was obtained. Screening for TB disease in
children included history, examination, chest radiography, TST
and IGRA tests, and microbiology if indicated. The evaluation
of contacts to decide on the provision of treatment for TB infec-
tion was based on NICE guidelines, in conjunction with clinical
context. Children with TB infection were treated with isoniazid
and rifampicin daily for 3 months.
TST and IGRA were evaluated at baseline. TSTwas placed by
experienced members of the local TB nursing teams, by inject-
ing two tuberculin units intradermally (puriﬁed protein deriva-
tive RT23, Statens Serum Institute) with results read at 48–72 h.
IGRA tests (either QuantiFERON-TB Gold In-Tube (Cellestis
Ltd) or T-SPOT.TB (Oxford Immunotec Ltd) depending on the
practice of the recruiting clinic) were carried out by the clinic-
ally available laboratory services, following the manufacturer’s
speciﬁcations. The IGRA test was repeated in all children after
2 months. If the TST was negative at baseline, it was also
repeated after 2 months. TST was deﬁned as being positive if
the transverse diameter of the induration was ≥6 mm in
BCG-unvaccinated children and ≥15 mm in vaccinated children,
in line with the 2006 NICE recommendations. The largest TST
measurement was used for analysis. The child was classiﬁed as
IGRA positive (and hence assumed to be TB infected for the
purposes of this analysis) if either the baseline or the 2-month
IGRA was positive. Repeatedly indeterminate results were con-
sidered negative. Children were examined for the presence of a
BCG scar; if present, children were classiﬁed as BCG vaccinated.
If no scar was seen, but there was clear documentation in paper
or electronic records, or if the parents gave a clear history of
vaccination, the child was classiﬁed as BCG vaccinated.
Otherwise the child was classiﬁed as BCG unvaccinated.
Statistical analysis
Data were entered into a tailor-made online database in real
time and later checked centrally for entry errors. Data were ana-
lysed using STATA software (V.11; Stata Corp, College Station,
Texas, USA). For analysis, children were divided into four age
groups: <2 years, 2 to <5 years, 5 to <10 years and 10 to
<15 years. The Mann–Whitney test was used to assess differ-
ences between TST measurements in BCG vaccinated and
unvaccinated children due to the non-normal distribution of the
data. ORs and 95% CIs were calculated to determine the
Table 3 Odds of having a positive TST response of 5 mm, 10 mm and 15 mm between IGRA negative children who had been vaccinated with
BCG at birth versus children who had not been vaccinated with BCG
5 mm 10 mm 15 mm
Age (years) OR (95% CI) p Value OR (95% CI) p Value OR (95% CI)* p Value
All children 5.80 (2.58 to 13.0) <0.001 4.03 (1.73 to 9.39) <0.001 3.04 (1.14 to 8.10) 0.02
0 to <2 16.2 (1.69 to 155) 0.001 8.31 (0.94 to 73.5) 0.02 − 0.05
2 to <5 9.85 (1.11 to 87.7) 0.01 7.43 (0.85 to 65.1) 0.03 6.00 (0.69 to 52.4) 0.06
5 to <10 3.05 (0.93 to 10.0) 0.05 2.71 (0.72 to 10.3) 0.13 1.92 (0.39 to 9.52) 0.41
10 to <15 4.16 (0.77 to 22.3) 0.07 2.10 (0.39 to 11.2) 0.38 0.90 (0.15 to 5.32) 0.91
*Unable to calculate ORs where a zero exists in one of the four cells needed to generate the OR. No BCG-unvaccinated children under 2 years with negative IGRA results had a TST
induration of greater than 15 mm. IGRA, interferon γ release assay; TST, tuberculin skin test.
Table 2 Median TST induration in BCG-vaccinated and BCG-unvaccinated children at different ages who are IGRA negative
All children BCG vaccinated BCG unvaccinated
Age (years) Number Median TST (IQR) Number Median TST (IQR) Number Median TST (IQR) p Value
All children 314 0 (0–6) 228 0 (0–10) 86 0 (0–0) <0.001
0 to <2 76 0 (0–10) 57 4 (0–12) 19 0 (0–0) <0.001
2 to <5 80 0 (0–4) 55 0 (0–8) 25 0 (0–0) 0.001
5 to <10 102 0 (0–5) 75 0 (0–10) 27 0 (0–3) 0.12
10 to <15 56 0 (0–7) 41 0 (0–8) 15 0 (0–0) 0.09
IGRA, interferon γ release assay; TST, tuberculin skin test.
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impact of BCG vaccination on TST positivity, in IGRA-negative
children, using three TST cut-offs (5, 10 and 15 mm).
Sensitivity, speciﬁcity, PPV, NPV, together with receiver operator
characteristic (ROC) curves and their respective area under the
curves were determined for different TST cut-offs to predict
IGRA positivity. 95% CIs were determined for each of the
above.
RESULTS
Of 422 children recruited, 216 (51%) were boys; median age
was 69 months (IQR: 32–113). Of 370 children tested for HIV,
none tested positive and no children in the study were known
to be HIV positive. The majority of children (361; 86%) were
born in the UK. Three hundred (71%) had been vaccinated with
BCG (table 1).
In IGRA-negative children <2 years, there was a difference in
TST size between those who were BCG vaccinated and those
who were unvaccinated (median: 4 mm (IQR: 0–12) vs median:
0 mm (IQR: 0–0); p<0.001; table 2). There was also a differ-
ence for children aged 2 years to <5 years (p=0.001) but no
signiﬁcant difference was seen in children aged 5 to <10 years
(p=0.12) or children aged 10 to <15 years (p=0.09) (table 2).
For IGRA-negative children aged <2 years and 2 to <5 years,
those who were BCG vaccinated were more likely to have a
positive TST result than those who were unvaccinated, at all
three TST cut-offs. For children aged 5 to <10 years and 10 to
<15 years there was a smaller and less signiﬁcant difference in
TST positivity between children who were BCG vaccinated and
those who were unvaccinated, at all TST cut-offs (table 3).
In BCG-unvaccinated children, the use of a 5 mm or a 10 mm
TST cut-off to predict IGRA positivity resulted in similar sensi-
tivities and speciﬁcities and provided excellent NPVs at all ages
(table 4). For all ages of unvaccinated children, the area under
the ROC curve was above 0.94 (ﬁgure 1). For children under
5 years who had been vaccinated with BCG, the sensitivity and
speciﬁcity of TST to predict IGRA positivity was low using all
three cut-offs (table 5). In older children, good sensitivities were
seen using 5 or 10 mm, but at 5 mm speciﬁcity was poor. By
using a 15 mm cut-off the speciﬁcity improved, but at the
expense of sensitivity. For BCG-vaccinated children under
5 years, the area under the ROC curve was below 0.8. However,
in children over 5 years, the area under the curve was greater
than 0.9.
DISCUSSION
This large UK cohort study of paediatric household TB contacts
shows that BCG vaccination had little effect on TST size in chil-
dren over 5 years of age. In younger children, BCG did affect
TST measurements, but as age increased this effect was less pro-
nounced. In BCG-unvaccinated children, 5 and 10 mm TST
cut-offs showed good sensitivity and speciﬁcity to detect TB
infection, deﬁned as IGRA positivity, while 15 mm was asso-
ciated with impaired sensitivity. In BCG-vaccinated children,
TST performed poorly in children under 5 years in terms of the
sensitivity and speciﬁcity to predict IGRA positivity, but
appeared to be reliable in children over this age, with 10 and
15 mm cut-offs providing reasonable sensitivity and speciﬁcity.
Although this topic has been evaluated in other settings, we
have not been able to identify any studies carried out previously
in the UK. A systematic review of studies that evaluated the
impact of BCG on TST found that if vaccination was given at
birth, the impact on TST size waned fairly rapidly and by the
age of 10 years less than 1% of children had a TSTof 10 mm or
greater.16 If BCG was given after the ﬁrst year of life, however,
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a much higher proportion of children remained TST positive. In
line with our own data, a recent study from Spain found that
the risk of a false-positive TST result, due to BCG given at birth,
disappeared by 3 years post vaccination.17 Similar ﬁndings were
also reported from a study conducted in Canada, where the
data showed that when using a 5 mm cut-off, TST positivity was
higher in children of all ages who had been vaccinated at birth
compared with unvaccinated children. However, after 1 year,
when using a cut-off of 15 mm, the rate of TST positivity was
no different in vaccinated children. When using a cut-off of
10 mm, more vaccinated children had a positive TST at the age
of 1 year, but by 4 years of age, no differences were seen.18
Using different TST size cut-offs for BCG vaccinated and unvac-
cinated children is not a universal policy. A recent review of
national and international childhood TB guidelines found that
most countries and agencies use a 10 mm induration cut-off for
all children irrespective of BCG vaccination status,19 in line with
the advice of WHO.14
To inform policy it is important to obtain evidence from the
population for whom the policy is intended. To this end, this
large study of children living in the UK, evaluated post exposure
to infectious cases of pulmonary TB, is informative. This is
especially so in the context of the recent revision to the NICE
guidelines for the management of TB in the UK where a TST
cut-off of 5 mm has been recommended for all ages of children
irrespective of BCG vaccination history.15
This study has some acknowledged limitations. The ﬁrst limi-
tation was that we used the UK NICE 2006 deﬁnitions of TST
positivity to decide if a second TSTwas required. Therefore, for
BCG-unvaccinated children, those with an initial TST of ≥6 mm
did not have a repeat test after 2 months. Although this prag-
matic approach reﬂected UK policy, it may have resulted in TST
measurements for BCG-vaccinated children being lower than if
we had repeated the TST in all children and used the largest
TST response in analysis. A second limitation was that as this
study was carried out under programmatic conditions, some
data were missing. Although, the absolute numbers were small,
the most common missing data were repeat TST testing for
those children with initially negative tests (ﬁve children). Third,
as we were using routine, clinical data for IGRA testing, some
centres used QuantiFERON-TB Gold In-Tube and some
T-SPOT.TB. Although it would have been ideal to have used the
same test for all children, we, and other research groups, have
previously shown these two IGRA tests to be highly concordant
and it was a deliberate decision of the principal investigator and
the collaborators to use their locally available IGRA.10 20–22
Fourth, we used evidence of a BCG scar, documentation of vac-
cination, or a clear history of vaccination from the parents as
evidence of BCG vaccination. It is possible that some children
were incorrectly classiﬁed using this approach. Fifth, although
the majority of children were vaccinated soon after birth, we
were unable to document exactly when each child received the
Figure 1 Receiver operating characteristic curves for tuberculin skin test results of different cut-offs to predict interferon γ release assay positivity.
(A) BCG-unvaccinated children <2 years (n=20; AUC=1.00; 95% CI not calculable). (B) BCG-vaccinated children <2 years (n=64; AUC=0.79; 95% CI
0.65 to 0.93). (C) BCG-unvaccinated children aged 2 to <5 years (n=32; AUC=0.97; 95% CI 0.91 to 1.00). (D) BCG-vaccinated children aged 2 to
<5 years (n=65; AUC=0.78; 95% CI 0.60 to 0.95). (E) BCG-unvaccinated children aged 5 to <10 years (n=41; AUC=0.95; 95% CI 0.88 to 1.00). (F)
BCG-vaccinated children aged 5 to <10 (n=108; AUC=0.92; 95% CI 0.86 to 0.97). (G) BCG-unvaccinated children aged 10 to <15 (n=29;
AUC=0.99; 95% CI 0.96 to 1.00). (H) BCG-vaccinated children aged 10 to <15 (n=63; AUC=0.95; 95% CI 0.90 to 1.00).
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BCG. This makes it more difﬁcult to determine how quickly the
effects of BCG on TST responses wane. Sixth, this study was
carried out in the UK and caution should be exercised when
generalising results to other contexts. We anticipate that similar
ﬁndings would be seen in countries with a similar epidemio-
logical TB pattern but it should be acknowledged that the PPVs
and NPVs would likely change with the background TB preva-
lence and consequent pre-test probability that the child was
IGRA positive. Seventh, although all children were exposed to
TB in their households, it is theoretically possible that children
living in areas that recommended BCG vaccination were, in
some way, more exposed to TB than children from other
regions in the UK. This could have led to some degree of selec-
tion bias that might have impacted on TST responses. Eighth, it
is possible that in some of the age subgroups, the sample size
was not large enough to detect modest variations in TST
response due to BCG, especially in older children. Finally, and
most importantly, we used the IGRA result as the ‘gold standard’
to deﬁne who was genuinely infected and compared different
TST cut-offs in BCG vaccinated and unvaccinated children
against this result. It is acknowledged that IGRA tests have
imperfect sensitivity and speciﬁcity, especially in younger chil-
dren.10 22 It is therefore possible that some IGRA-negative chil-
dren who had a reactive TST were actually infected and their
positive TST response may have been due to M. tuberculosis.
These would have been classiﬁed as false positives. Conversely
some IGRA-positive children with unreactive TST responses may
not have been infected with M. tuberculosis. These children
would have been classiﬁed as false negatives. As we sought to
determine the impact of BCG on TST responses in children, we
used IGRA as a tool to screen out the majority of the TST
responses that were caused by genuine TB infection and not
BCG. Although there may have been one or two misclassiﬁca-
tions, we are conﬁdent that the overall result is valid.
Our study suggests that in the youngest children BCG does
affect TST measurements. However, these children are the most
vulnerable to progression from infection to disease and are also
the most susceptible to severe disseminated forms of TB disease,
such as TB meningitis and miliary TB. Because of this, greater
screening test sensitivity and a high NPV is more important
than speciﬁcity and PPV for many clinicians when evaluating
children in this age group. WHO recommends treating all chil-
dren aged under 5 years for TB infection following signiﬁcant
exposure to an infectious TB case, irrespective of the result of
the test of TB infection and irrespective of BCG vaccination
status.23
For those managing TB in children, there is a need to con-
sider the interpretation of screening tests. As no tests are perfect
there will always be a trade-off between sensitivity and speciﬁ-
city of the test chosen as well as their respective PPVs and
NPVs. The question of whether it is better to treat some chil-
dren for TB infection unnecessarily (because of greater test sen-
sitivity) or to fail to treat some children with TB infection who
may progress to disease (because of greater test speciﬁcity)
remains challenging. Although 6 months of daily isoniazid is a
long course of treatment for a child who is well, it is safe24 and
effective.8 25 Three months of daily isoniazid and rifampicin has
been shown to be an appropriate alternative strategy.26 Ideally,
tests with a high NPV are used for screening, while tests for
diagnosis should have a high PPV. However, both false negatives
Figure 1 Continued.
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and false positives have clinical and cost implications. Modelling
exercises suggest that not only is the treatment of TB infection
in children likely to be a highly cost-effective strategy, but in
children under 2 years old, screening for exposure and treating
without testing for evidence of infection is the most cost-
effective intervention.27 As newer, simpler treatments become
available, such as the 3-month duration once-a-week regimen
with rifapentine and isoniazid,28 29 the beneﬁts of treating may
increasingly outweigh the risks and costs and of not treating
younger children.
CONCLUSION
Our data suggest that the impact of infant BCG vaccination on
TST responses in children exposed to TB wanes with age. In
BCG-vaccinated children a TST cut-off of 5 mm is associated
with poor speciﬁcity.
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